Articles tagged with Type 2 Diabetes
Researchers analyzed insurance claims data from US health insurers to demonstrate the cardiovascular benefits of semaglutide and tirzepatide. Both GLP-1 drugs provide cardioprotective effects, reducing the risk of stroke and heart attack by 18% and 13%, respectively.
Researchers found that prasugrel may offer an advantage over ticagrelor for individuals with Type 1 or Type 2 diabetes and complex coronary disease. This is because the two medications are not interchangeable, and treatment with prasugrel may provide better benefits in preventing blood clots and adverse cardiac events.
A new poll finds that 65% of Americans would try a low-fat, plant-based diet to prevent type 2 diabetes or improve blood sugar control. The poll also reveals that most adults are unaware of the benefits of high fruit and vegetable intake for reducing diabetes risk.
A comprehensive analysis of 70,000 participants across 10 trials found that SGLT2 inhibitors reduced the risk of chronic kidney disease (CKD) progression by 38% and slowed eGFR decline by 51%. The treatment was beneficial for all levels of kidney function and albuminuria levels, particularly in reducing hospitalizations.
The study suggests that SGLT2 inhibitors can benefit patients with varying levels of kidney function and albuminuria. Routine use of these medications may lead to improved kidney outcomes across different patient groups.
Researchers explore the link between senescent cells and metabolic diseases, highlighting potential treatments known as senotherapeutics. Senolytics, senomorphics, and senosensitizers are interventions aimed at eliminating or suppressing senescent cells to mitigate metabolic disease.
A new study found that combining GLP-1 receptor agonist medications with healthy lifestyle habits significantly reduces the risk of major adverse cardiovascular events, including heart attacks and strokes. The research suggests that adopting multiple healthy behaviors can lower cardiovascular risk even further.
A study found that following steps to improve cardiovascular health can reduce the risk of mild cognitive impairment and dementia among people with Type 2 diabetes. Maintaining optimal cardiovascular health may protect brain health even for individuals with a high genetic risk for dementia.
A preliminary study found that low-dose aspirin use was associated with a lower risk of major cardiovascular events, including heart attacks and strokes, among adults with Type 2 diabetes. The analysis of 11,500 individuals over 10 years showed that consistent aspirin use led to significant reductions in cardiovascular event rates.
A new observational study found that semaglutide, tirzepatide, and dulaglutide have similar gastrointestinal safety profiles among patients with type 2 diabetes. The medications were assessed in a large database of adults with T2D, who underwent treatment with these GLP-1 RA medications between 2019 and 2024.
Type 2 diabetes has become a global epidemic with unequal burden, driven by ageing, dietary shifts, sedentary behaviour, and early-life exposures. The true cost of diabetes includes significant healthcare and economic burdens, but prevention remains the weakest link.
This cross-sectional study found an increase in GLP-1RA prescriptions, with Tirzepatide and semaglutide growing the fastest due to their superior glycemic, weight loss, and guideline-emphasized cardiorenal benefits. However, coverage for obesity is limited, especially among off-label semaglutide use in non-T2D patients.
Frequent continuous glucose monitoring (CGM) use is associated with better glycemic control in people with type 2 diabetes. Clinicians should encourage CGM use and monitor its impact on therapy.
Researchers found that magnetic mitohormesis, a non-invasive treatment, can activate metabolic pathways triggered by exercise, improving glucose control without physical strain. Patients with excess belly fat experienced significant improvements in blood glucose control and HbA1c levels.
Researchers develop a compound that reduces cell death, inflammation, and organ damage in diabetes. The drug candidate, RAGE406R, prevents the interaction between two proteins that enable heart and kidney injury, and accelerates wound closure.
Three new Cochrane reviews found GLP-1 drugs result in clinically meaningful weight loss, but evidence on longer-term outcomes and side effects is limited. The wider use of these drugs should consider social and commercial determinants to avoid deepening existing health inequities.
A new study published in PLOS One found that nearly one-third of adults with type 2 diabetes in India achieved remission through a comprehensive mobile-based program combining diet, exercise, stress management, and medical support. The program showed significant improvements in weight, body mass index, glycated hemoglobin levels, fasti...
A recent study published in Pediatric Research highlights the impact of neighborhood environments on childhood type 2 diabetes risk. The research found associations between library presence, neighborhood walkability, and caregiver health, suggesting that social and environmental factors play a significant role in T2D development.
Researchers found SGLT-2 inhibitors reduce autoimmune rheumatic diseases by 11% compared to sulfonylureas. The study analyzed over 2 million adults with type 2 diabetes and suggests these drugs may contribute to a lower risk of autoimmune diseases.
This study found that GLP-1RAs and SGLT2is offer the greatest cardiovascular benefits for adults with type 2 diabetes. The magnitude of benefit depends on baseline age, atherosclerotic cardiovascular disease, heart failure, and kidney impairment.
A comparative effectiveness study found that liraglutide, semaglutide, and dulaglutide have similar risks for kidney and cardiovascular outcomes in veterans with type 2 diabetes. Head-to-head trials are needed to confirm these findings.
A study of 5,794 adults found that different types of depression are associated with varying levels of risk for cardiometabolic diseases. Those with atypical/energy-related symptoms were more likely to develop Type-2 diabetes, while those with melancholic symptoms were at higher risk for cardiovascular disease.
Researchers at City of Hope have identified a gene called SMOC1 that converts insulin-producing cells into those that increase blood sugar, shedding light on the progression of type 2 diabetes. This discovery offers new therapeutic targets and potential treatments for T2D.
A recent study found that primary care providers in Ohio perceive and treat opioid use disorder (OUD) differently from other chronic conditions like type 2 diabetes. Despite recognizing OUD as a chronic brain disease, providers were less likely to offer treatment themselves.
A study conducted at the University of Eastern Finland found that group-based and online lifestyle counselling can help middle-aged and older men adopt healthier dietary habits, leading to a lower risk of type 2 diabetes. Those with a high genetic risk for type 2 diabetes saw the most significant benefits from fibre-rich diets.
A new study found that AI tool accurately captures details in just three minutes from a body scan, highlighting the potential of using AI to repurpose data from routine scans. Visceral adipose tissue volume and fat deposits in muscle are strongly associated with diabetes and cardiovascular disease risk.
A new study published in Diabetes, Obesity and Metabolism found that weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes. The study analyzed data from over 180,000 people and found a significant reduction in cancer incidence ...
A 'light-touch' EHR referral strategy successfully connected patients with prediabetes to community-based DPPs, with 122 out of 577 referred patients enrolling. The strategy was used by 30% of targeted clinicians and accounted for over half of all referrals.
The SURPASS-PEDS trial shows that tirzepatide significantly improves HbA1c levels, BMI, and fasting glucose in children aged 10-17 years with type 2 diabetes. The study demonstrates sustained improvements over a year-long period, making it a potential safe and efficacious treatment option for youth-onset type 2 diabetes.
A UK Biobank study suggests that people with type 2 diabetes progress to additional chronic conditions at a faster rate than those without the condition. The study found that individuals with T2D experience a 60% higher risk of new disease diagnosis compared to those without T2D.
A diet rich in wholegrains, fruits, and vegetables while limiting red meat and sugary drinks may help prevent type 2 diabetes and reduce greenhouse gas emissions. Higher adherence to this planetary health diet was associated with a 32% lower incidence of type 2 diabetes and 18% lower greenhouse emissions.
A new study published in Pharmaceutics found that semaglutide provides powerful protection against diabetic retinopathy, a condition that can lead to sight loss. The study suggests that GLP-1 receptor agonists enhance retinal cells' defences against damage in diabetes-like conditions.
A large community-based study has found that individuals with type 2 diabetes are at a doubled risk of developing sepsis, particularly among younger adults and men. The study identified several modifiable risk factors, including smoking, high blood sugar, and complications of diabetes.
A systematic review and meta-analysis of 18 trials found GLP-1 RAs significantly improved glycemic and weight outcomes in children and adolescents with type 2 diabetes or obesity. However, gastrointestinal adverse effects warrant attention in long-term management.
Two large-scale clinical trials found that a higher dose of semaglutide significantly improves weight loss and related health outcomes in adults with obesity. The study revealed an average weight loss of nearly 19% in those receiving the higher dose, compared to 10% with the standard dose or placebo.
Women with type 2 diabetes taking oral hormone replacement therapy are at a higher risk of developing pulmonary embolism and heart disease. Transdermal HRT, on the other hand, appears safer, reducing cardiovascular risk by up to 25%.
A new study analyzing real-world data from over 4 million adults found that cannabis users face almost four times the risk of developing type 2 diabetes within five years compared to non-users. The study suggests that long-term metabolic effects of cannabis use may be linked to insulin resistance and unhealthy dietary behaviors.
A new European study of over 45,000 individuals aged 50-plus found a significant association between diabetes and depression, with individuals having diabetes increasing their risk of developing severe depressive symptoms by 48%, regardless of country. Conversely, those with high depressive symptoms had a 15% higher odds of developing ...
Research from Sweden, Norway, and Finland shows smoking significantly raises type 2 diabetes risk across all subtypes, with severe insulin-resistant diabetes (SIRD) being the most affected. Heavy smokers face greater risks, especially those with genetic predispositions.
Researchers found genetic peptides called alpha-defensins that shape gut bacteria, producing healthier microbiomes and reducing insulin resistance. This discovery suggests personalized treatments can be tailored to individual genes, offering new hope for addressing chronic diseases like obesity and diabetes.
A 14-year study highlights the importance of diagnosing and treating obstructive sleep apnea in people with type 2 diabetes. The research suggests that continuous positive airway pressure (CPAP) treatment can reduce mortality risk by up to 26%.
A cohort study found GLP-1 RAs offer body mass index-dependent cardiovascular benefits and consistent kidney protection for type 2 diabetes patients. The study suggests BMI stratification is crucial for guiding treatment decisions.
Researchers at the University of Gothenburg found that semaglutide reduced both cocaine use and relapse in rats, with motivation to keep taking cocaine decreasing by 52%. The study suggests that semaglutide may blunt cocaine's ability to raise dopamine levels in the brain.
Researchers found 22 previously unknown genetic variants associated with type 2 diabetes by considering participants' hormone levels. The analysis suggests that sex hormone levels interact with genes to increase the risk of developing the disease.
Researchers discovered a brain-liver circuit that connects stress with increased glucose production, potentially linking to type 2 diabetes. Long-term elevations in glucose can cause hyperglycemia and increase the risk of developing type 2 diabetes.
Research found that people with learning disabilities in the UK have a faster progression to severe type 2 diabetes and are at higher risk of dying from the condition. They also tend to have better overall blood glucose control compared to those without learning disabilities.
Researchers found that diabetes directly affects the heart's structure and energy production in humans for the first time. Diabetes causes distinct molecular changes to heart cells and structural changes to the muscle, particularly in patients with ischaemic cardiomyopathy.
A Kobe University study found that metformin reduces copper and iron levels and increases zinc levels in patients with type 2 diabetes. This suggests a possible mechanism for the drug's beneficial effects beyond lowering blood sugar levels.
Human cells use a synchronized traffic control system to monitor nutrient levels and precisely control cellular energy balance, blood sugar levels, and energy management. This finding offers promising new targets for treating diabetes and cancer.
A new investigational drug, ION224, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. By targeting the DGAT2 enzyme, the drug helps reduce fat buildup and inflammation, two major drivers of liver damage.
The Pennington Biomedical Research Center has opened a new Endocrinology and Diabetes Clinic in Baton Rouge, providing specialized care for patients managing diabetes and endocrine disorders. The clinic is led by Dr. Timothy Gilbert, who brings nearly 20 years of private practice experience to the region.
A Mediterranean-style diet, along with reduced caloric intake and moderate physical activity, has been shown to lower the risk of type 2 diabetes by 31%. The study found that participants in the intervention group lost an average of 3.3 kilograms and reduced their waist circumference by 3.6 centimeters.
A new study found that younger men with type 2 diabetes are more likely to experience worse cardiovascular disease and mortality outcomes compared to those with type 1 diabetes. In contrast, women with type 1 diabetes face poorer health outcomes across all ages, particularly due to longer exposure to high blood sugar levels and less ag...
A new study from the Indian Institute of Science (IISc) reveals that glucose uptake is poorly managed in β-cells from people with Type 2 diabetes, leading to reduced insulin secretion. Restoring proper GLUT trafficking could slow disease progression and personalize therapies, according to the researchers.
Researchers developed a first-trimester blood test that accurately predicts gestational diabetes risk, using just seven biomarkers. The test's strong ability to distinguish high-risk from low-risk pregnancies could enable early interventions and reduce long-term health burdens.
A study found that almost 50,000 adults with prediabetes and 30,000 with type 2 diabetes lived in the same households as index cases. The researchers analyzed electronic health records to identify household members with diabetes risk factors, including obesity and abnormal blood fats.
Researchers at the University of Sydney have discovered a new biological pathway that may help explain why people with type 2 diabetes are more prone to developing blood clots. A protein called SEC61B was found to disrupt calcium balance inside platelets, making them more likely to form clots.
Cohort study finds GLP-1 receptor agonist use associated with modestly increased risk of incident diabetic retinopathy; however, those with preexisting DR experience fewer sight-threatening complications. Regular screening and monitoring recommended for all T2D patients on GLP-1 RAs.
A new study published in JAMA Network Open reveals that patients with type 2 diabetes prescribed semaglutide or tirzepatide are at increased risk of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders. The overall risk is low, but highlights the need for close monitoring of these conditions.
An international research team has identified epigenetic biomarkers that can predict which individuals with type 2 diabetes are at risk of cardiovascular disease. The study used DNA methylation as a way to identify these biomarkers in blood, and found over 400 sites with altered DNA methylation.